Erythropoiesis in cancer patients undergoing immunotherapy

J. L. Ascensao, S. J. Liu, J. Caro, E. Podack, A. Mittelman, E. D. Zanjani, Y. L. Zhao

Research output: Chapter in Book/Report/Conference proceedingConference contribution

3 Citations (Scopus)

Abstract

We studied ten patients with various types of cancer who were being treated with Interleukin-2 (IL-2) and lymphokine activated killer cells (LAK). All patients developed a reticulocytopenic, normochromic, normocytic anemia. We noted some variability but no significant suppression of circulating erythroid progenitors. The levels of erythropoietin were lower than expected for the hemoglobin/hematocrit values. We could not detect Interferon or Tumor Necrosis Factor (TNF) in the serum of these patients; however, the supernatant of LAK cells did contain Interferon and TNF which could be neutralized with appropriate antibodies. These results suggest that the etiology of this anemia is multi-factorial. Administration of recombinant erythropoietin (Ep) may be of benefit in some of these patients.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
Pages197-204
Number of pages8
Volume271
StatePublished - Oct 2 1990
Externally publishedYes

Fingerprint

Lymphokines
Erythropoiesis
Erythropoietin
Immunotherapy
Interferons
Tumor Necrosis Factor-alpha
Lymphokine-Activated Killer Cells
Interleukin-2
Anemia
Neoplasms
Hemoglobins
Antibodies
Hematocrit
Serum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ascensao, J. L., Liu, S. J., Caro, J., Podack, E., Mittelman, A., Zanjani, E. D., & Zhao, Y. L. (1990). Erythropoiesis in cancer patients undergoing immunotherapy. In Advances in Experimental Medicine and Biology (Vol. 271, pp. 197-204)

Erythropoiesis in cancer patients undergoing immunotherapy. / Ascensao, J. L.; Liu, S. J.; Caro, J.; Podack, E.; Mittelman, A.; Zanjani, E. D.; Zhao, Y. L.

Advances in Experimental Medicine and Biology. Vol. 271 1990. p. 197-204.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Ascensao, JL, Liu, SJ, Caro, J, Podack, E, Mittelman, A, Zanjani, ED & Zhao, YL 1990, Erythropoiesis in cancer patients undergoing immunotherapy. in Advances in Experimental Medicine and Biology. vol. 271, pp. 197-204.
Ascensao JL, Liu SJ, Caro J, Podack E, Mittelman A, Zanjani ED et al. Erythropoiesis in cancer patients undergoing immunotherapy. In Advances in Experimental Medicine and Biology. Vol. 271. 1990. p. 197-204
Ascensao, J. L. ; Liu, S. J. ; Caro, J. ; Podack, E. ; Mittelman, A. ; Zanjani, E. D. ; Zhao, Y. L. / Erythropoiesis in cancer patients undergoing immunotherapy. Advances in Experimental Medicine and Biology. Vol. 271 1990. pp. 197-204
@inproceedings{4dab22b7fb0e44be82f56de6a1213061,
title = "Erythropoiesis in cancer patients undergoing immunotherapy",
abstract = "We studied ten patients with various types of cancer who were being treated with Interleukin-2 (IL-2) and lymphokine activated killer cells (LAK). All patients developed a reticulocytopenic, normochromic, normocytic anemia. We noted some variability but no significant suppression of circulating erythroid progenitors. The levels of erythropoietin were lower than expected for the hemoglobin/hematocrit values. We could not detect Interferon or Tumor Necrosis Factor (TNF) in the serum of these patients; however, the supernatant of LAK cells did contain Interferon and TNF which could be neutralized with appropriate antibodies. These results suggest that the etiology of this anemia is multi-factorial. Administration of recombinant erythropoietin (Ep) may be of benefit in some of these patients.",
author = "Ascensao, {J. L.} and Liu, {S. J.} and J. Caro and E. Podack and A. Mittelman and Zanjani, {E. D.} and Zhao, {Y. L.}",
year = "1990",
month = "10",
day = "2",
language = "English",
volume = "271",
pages = "197--204",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - GEN

T1 - Erythropoiesis in cancer patients undergoing immunotherapy

AU - Ascensao, J. L.

AU - Liu, S. J.

AU - Caro, J.

AU - Podack, E.

AU - Mittelman, A.

AU - Zanjani, E. D.

AU - Zhao, Y. L.

PY - 1990/10/2

Y1 - 1990/10/2

N2 - We studied ten patients with various types of cancer who were being treated with Interleukin-2 (IL-2) and lymphokine activated killer cells (LAK). All patients developed a reticulocytopenic, normochromic, normocytic anemia. We noted some variability but no significant suppression of circulating erythroid progenitors. The levels of erythropoietin were lower than expected for the hemoglobin/hematocrit values. We could not detect Interferon or Tumor Necrosis Factor (TNF) in the serum of these patients; however, the supernatant of LAK cells did contain Interferon and TNF which could be neutralized with appropriate antibodies. These results suggest that the etiology of this anemia is multi-factorial. Administration of recombinant erythropoietin (Ep) may be of benefit in some of these patients.

AB - We studied ten patients with various types of cancer who were being treated with Interleukin-2 (IL-2) and lymphokine activated killer cells (LAK). All patients developed a reticulocytopenic, normochromic, normocytic anemia. We noted some variability but no significant suppression of circulating erythroid progenitors. The levels of erythropoietin were lower than expected for the hemoglobin/hematocrit values. We could not detect Interferon or Tumor Necrosis Factor (TNF) in the serum of these patients; however, the supernatant of LAK cells did contain Interferon and TNF which could be neutralized with appropriate antibodies. These results suggest that the etiology of this anemia is multi-factorial. Administration of recombinant erythropoietin (Ep) may be of benefit in some of these patients.

UR - http://www.scopus.com/inward/record.url?scp=0025147619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025147619&partnerID=8YFLogxK

M3 - Conference contribution

C2 - 2518599

AN - SCOPUS:0025147619

VL - 271

SP - 197

EP - 204

BT - Advances in Experimental Medicine and Biology

ER -